Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugemalimab in Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma
NCT03595657Phase 2Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of sugemalimab in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by CStone Pharmaceuticals. Started Jun 2018; status: completed.
02
Drugs
sugemalimab
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT03595657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03595657.